HC Wainwright keeps USD 38.00 target for Syndax Pharmaceuticals stock

Published on 10/15/2026 at 13:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Syndax kept its USD 38.00 target on October 13, 2026. Syndax Pharmaceuticals stock trades at EUR 12.14 on October 15, 2026.

Pipeline setback and valuation

HC Wainwright maintained a USD 38.00 target on October 13, 2026.
Syndax reported USD 72.79 million in second-quarter revenue, up 91.80 percent year over year.
Syndax Pharmaceuticals stock traded at EUR 12.14 at 1:07 p.m. CEST at Lang & Schwarz on October 15, 2026.

SNDX, US87164F1057, Illustration mit AI erstellt.

Syndax Pharmaceuticals (ISIN US87164F1057) was trading at EUR 12.14 at Lang & Schwarz on October 15, 2026 at 1:07 p.m. CEST. The company had a USD 38.00 price target maintained by HC Wainwright on October 13, 2026, according to MarketBeat.

Trial setback changes the focus

On October 12, 2026, Syndax announced that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint. The release said axatilimab was well tolerated and that its safety profile was comparable to placebo, while development in the indication was set to end, according to Syndax Pharmaceuticals.

The failed study removes one development path for axatilimab, increasing the importance of Syndax's approved oncology products and ongoing chronic graft-versus-host disease programs. HC Wainwright's maintained target shows that the firm continued to value those assets after the trial update.

What does the revenue base mean?

Syndax reported USD 72.79 million in revenue for the second quarter of 2026, up 91.80 percent from USD 37.96 million in the second quarter of 2025. The same report showed a GAAP net loss of USD 49.36 million, compared with USD 71.85 million a year earlier, according to Markets Insider.

Three dated developments

On August 4, 2026, Syndax reported USD 72.79 million in second-quarter revenue. On October 12, 2026, the MAXPIRe trial missed its primary endpoint and the stock fell 15.00 percent after hours, according to SquawkNews. On October 13, 2026, HC Wainwright maintained its USD 38.00 target.

Next date for investors

MarketBeat lists November 2, 2026 as the estimated date for Syndax's third-quarter 2026 results, with the conference call scheduled for 4:30 p.m. ET.

Stock valuation after the update

Syndax's market capitalization was USD 1.2 billion on October 15, 2026, while its primary Nasdaq listing had a 52-week range of USD 12.99 to USD 25.59 as of October 14, 2026. The euro quotation therefore remains a market reference for German investors, while the clinical result and the revenue trajectory define the company's next information points.

Syndax Pharmaceuticals stock was trading at EUR 12.14 at Lang & Schwarz on October 15, 2026 at 1:07 p.m. CEST.